Tarjinder Sahota

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of <scp>RIPK</scp>1 inhibitor <scp>GSK</scp>2982772 in healthy volunteers

Kathleen Weisel, Nicola Scott, Debra Tompson et al. · Pharmacology Research & Perspectives · 2017 · 130 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with <i>EGFR</i>-mutant, <i>MET</i>-driven (<i>MET</i>+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

Geoffrey R. Oxnard, Mireille Cantarini, Paul Frewer et al. · Journal of Clinical Oncology · 2019 · 37 citations

Medicine, Oncology, Pharmacology +16

Feasibility of a Fixed-Dose Regimen of Pyrazinamide and Its Impact on Systemic Drug Exposure and Liver Safety in Patients with Tuberculosis

Tarjinder Sahota, Oscar Della Pasqua · Antimicrobial Agents and Chemotherapy · 2012 · 26 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis

Tarjinder Sahota, Aliénor Berges, Sharon V. Barton et al. · CPT Pharmacometrics & Systems Pharmacology · 2015 · 20 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology

Núria Buil‐Bruna, Tarjinder Sahota, José M. López-Picazo et al. · Cancer Research · 2015 · 15 citations

Pharmacy, Oncology, Pharmacokinetics +17